Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AbbVie, Genentech, Takeda Oncology, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.
18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
February 14 - 15, 2014
Crowne Plaza® Times Square - Manhattan
New York, NY
OverviewThe 18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides a unique opportunity for medical oncologists, hematologists, and other health care professionals to learn from and to interact with international leaders in the field of hematologic malignancies in order to increase knowledge, apply new data and to practice and improve patient outcomes.
Target AudienceThis educational activity is directed toward community-based hematologists, medical oncologists, and fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
- Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of hematologic malignancies, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
- Summarize the genomic and molecular biomarkers that have been integrated into risk assessment and treatment selection paradigms for patients with hematologic malignancies
- Compare efficacy and safety data supporting treatment options in order to optimize outcomes for individual patients
- Describe current strategies for Individualizing therapy for patients with newly diagnosed hematologic malignancies based on assessment of transplant eligibility, patient and tumor characteristics, and risk/benefit profiles of available regimens
- Summarize optimal supportive care strategies for preventing and treating side effects related to hematologic malignancies or their treatment
- Select eligible patients with hematologic malignancies for promising clinical trials
It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial Support ℠, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (e.g., member of speaker’s bureau, grant/research support, or consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support to the participants.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
The following individuals have no relevant financial relationships with commercial interests to disclose:
Faculty and Staff Disclosures
Lisa DeAngelis, MD ; Randy Gascoyne, MD; Issa F. Khouri, MD; Thomas Kipps, MD, PhD; Ola Landgren, MD, PhD; Mark R. Litzow, MD; Susan Seo, MD; Catherine Wu, MD; Joachim Yahalom, MD
The staff of PER®, LLC: Leigh Anne Bongiovanni; Ann C. Lichti, CCMEP; Dru Dace, PhD; and Megan O'Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
James Berenson, MD — Grant/Research Support: Millennium; Celgene; Novartis; Amgen; Consultant: Celgene; Onyx; Novartis; Amgen; Millennium; Speaker’s Bureau: Celgene; Onyx; Novartis; Millennium; Leif Bergsagel, MD — Consultant: Onyx; Renier J. Brentjens, MD, PhD — Stock/Shareholder: Juno Therapeutics; Jennifer Brown, MD, PhD – Grant/Research Support: Celgene; Consultant: Pharmacyclics; Genentech; Emergent; Onyx; sanofi-aventis; Vertex; Novartis; Celgene; Boehringer; Gilead Sciences; GSK; Dan Douer, MD – Consultant: Sigma Tau; Amgen; BMS; Harry Erba, MD, PhD – Grant/Research Support: Celator; Millennium; Seattle Genetics; Amgen; Consultant: Novartis; Incyte; Seattle Genetics; Amgen; Speaker’s Bureau: Incyte; Novartis; Alessandra Ferrajoli, MD – Grant/Research Support: Celgene; Andre Goy, MD – Speaker’s Bureau: Millennium; Janssen; Advisory Board: Celgene; Janssen; Paul Hamlin, MD – Grant/Research Support: Spectrum; SGN; GSK; J&J; Consultant: Spectrum; Pfizer; Gilead; Sundar Jagannath, MD - Consultant: Celgene Corporation, Millennium Pharmaceuticals, and Merck & Co, Inc.; Ari Melnick, MD – Consultant: Celgene; Speaker’s Bureau: Genentech; BioReference; Ruben Mesa, MD, FACP – Grant/Research Support: Incyte; Genentech; Lillly; NS Pharma; Craig H. Moskowitz, MD – Grant/Research Support: Seattle Genetics; Roche; Plexxikon; Merck; Speaker’s Bureau: Janssen; Seattle Genetics; Roche; GlaxoSmithKlein; John Radford, MD – Grant/Research Support: Millennium/Takeda; Consultant: Seattle Genetics; Millennium/Takeda; Speaker’s Bureau: Seattle Genetics; Charles Schiffer, MD – Grant/Research: Novartis; BMS; Ariad; Celgene; Pfizer; Consultant: BMS; Teva; Celgene; Millennium; Pfizer; Speaker’s Bureau: BMS; A. Keith Stewart, M.B.Ch.B. – Grant/Research Support: Millennium; Onyx; Consultant: Celgene; Array Pharma; BMS; William G. Wierda, MD, PhD – Grant/Research Support: Genentech; Abbvie; GSK; Consultant: Genentech; Abbvie; GSK; Pharmacyclics; Gilead; Celgene; Anas Younes, MD – Research/Grant Support: Novartis; J&J; Seattle Genetics; Merck; Genentech; Gilead; Honorarium: Novartis; Seattle Genetics; Millennium; Celgene; Curis; sanofi-aventis; Pharmacyclics; Incyte; Andrew D. Zelenetz, MD, PhD – Research: Roche, GlaxoSmithKline, and Genentech; Consultant: Seattle Genetics, sanofi-aventis USA, GlaxoSmithKline, Gilead, Cephalon, and Celgene; Scientific Advisor: Cancer Genetics.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
Off-Label Disclosure and Disclaimer
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.